ストックスクリーナーアプリを入手
14.10
2.62%
0.37
前日終値:
$13.73
開ける：
$14.01
24時間の取引高:
3,544
Relative Volume:
0.03
時価総額：
$205.02M
収益：
$54,000
当期純損益:
$-210.26M
株価収益率:
-17.85
EPS:
-0.79
ネットキャッシュフロー:
$-159.01M
1週間 パフォーマンス:
+37.06%
1か月 パフォーマンス:
+57.61%
6か月 パフォーマンス:
+21.51%
1年 パフォーマンス:
-54.84%
1日の値動き範囲:
$13.78
$14.01
1週間の範囲:
$10.26
$14.18
52週間の値動き範囲:
$7.65
$34.40
Lyell Immunopharma Inc Stock (LYEL) Company Profile
名前
Lyell Immunopharma Inc
セクター
電話
650 695-0677
住所
201 HASKINS WAY, SOUTH SAN FRANCISCO
LYEL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
13.85 | 230.82M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.82 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.00 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
593.08 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.00 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-30 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-06-27 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-11-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | BofA Securities | Buy |
| 2021-07-12 | 開始されました | Goldman | Buy |
| 2021-07-12 | 開始されました | JP Morgan | Overweight |
| 2021-07-12 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Lyell Immunopharma Inc (LYEL) 最新ニュース
Visual trend scoring systems applied to Lyell Immunopharma Inc.High Conviction Stock Long-Term Summary - Newser
Buy Signal for Lyell Immunopharma Inc. Stock Key Technical Indicators to WatchAlgorithmic Forecast for Swing Trading Picks - Newser
Analyzing drawdowns of Lyell Immunopharma Inc. with statistical toolsReliable Setup Screener with Low Risk - Newser
Published on: 2025-07-29 03:38:25 - Newser
How to use a screener to detect Lyell Immunopharma Inc. breakoutsAlpha Stock Picks with Chart Confirmation - Newser
What is the dividend policy of Lyell Immunopharma Inc. stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
How to use a screener to detect Lyell Immunopharma Inc. breakouts Free Technical Entry Strategy for Beginners - Newser
What catalysts could drive Lyell Immunopharma Inc. stock higher in 2025Extraordinary profit generation - jammulinksnews.com
How volatile is Lyell Immunopharma Inc. stock compared to the marketInvest confidently with expert support - jammulinksnews.com
Sectors Driving Future Growth for Lyell Immunopharma Inc. StockHigh Potential Safe Trades - Newser
What makes Lyell Immunopharma Inc. stock price move sharplyElite Investor Club - Newser
What drives Lyell Immunopharma Inc. stock priceExceptional financial outcomes - PrintWeekIndia
Lyell Immunopharma $100M Deal: Can Buyers Hold the Stock After 20% Surge? - FXLeaders
Lyell Immunopharma $100M Deal: Can Buyers Extend the Stock After 20% Surge? - FXLeaders
Lyell Immunopharma (LYEL) Stock Soars Following Private Placement Announcement - FinancialBuzz.com
Lyell Immunopharma's $100M Private Placement: How Milestone-Driven Capital Raises De-Risk Biotechs and Create Asymmetric Upside - AInvest
What makes Lyell Immunopharma Inc. stock attractive to long term investorsExplosive capital appreciation - jammulinksnews.com
Lyell Immunopharma announces up to $100M equity private placement - TipRanks
Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News
Lyell Immunopharma Taps Investors For $100 Million In New Funding - Finimize
Is Lyell Immunopharma Inc. a good long term investmentBreakthrough profits - PrintWeekIndia
Lyell Immunopharma secures up to $100 million in private placement By Investing.com - Investing.com South Africa
Lyell Immunopharma Secures $100 Million in Private Placement - TipRanks
Why Lyell Immunopharma Inc. stock attracts strong analyst attentionROI Focused Stock Calls - Newser
Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewswire
Lyell Immunopharma Raises $100M to Advance Breakthrough Cancer Cell Therapy Through Pivotal Trials - Stock Titan
Is Lyell Immunopharma Inc. stock overhyped or has real potentialOutstanding capital returns - jammulinksnews.com
What analysts say about Lyell Immunopharma Inc. stockMarket-leading capital gains - PrintWeekIndia
Positive week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional investors who lost 70% over the past year - simplywall.st
Lyell Immunopharma Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com
Lyell Immunopharma's LYL314: A High-Risk, High-Reward Catalyst in the CAR T-Cell Space - AInvest
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement (LYEL) - Seeking Alpha
Lyell Immunopharma registers 625,000 shares for resale - MSN
Lyell Immunopharma Inc (LYEL) 財務データ
収益
当期純利益
現金流量
EPS
1.32%
1.06%
大文字化:
|
ボリューム (24 時間):